{
  "consolidation_metadata": {
    "timestamp": "2025-09-17T12:38:10.474898",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "picos",
    "total_consolidated_picos": 27,
    "source_countries": [
      "AT",
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_picos": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "AT",
        "DK",
        "EN",
        "NL",
        "PT",
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline",
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer",
        "patients with advanced NSCLC with a KRAS-G12C mutation that has progressed after at least one systemic therapy",
        "patients with nonâ€“small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation",
        "adult patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, in case of progression after at least one previous line of systemic therapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel monotherapy",
        "docetaxel",
        "docetaxel"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel plus nintedanib",
      "Countries": [
        "EN",
        "PT"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer"
      ],
      "Original_Comparator_Variants": [
        "docetaxel + nintedanib",
        "docetaxel plus nintedanib"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "pemetrexed"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "nivolumab"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "pembrolizumab"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "atezolizumab"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "platinum doublet",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "platinum doublet"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation who have progressed after at least one prior line of systemic therapy and who have been treated with docetaxel or who are not medically suitable for treatment with Docetaxel"
      ],
      "Original_Comparator_Variants": [
        "best supportive care"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "standard of care therapy",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy"
      ],
      "Original_Comparator_Variants": [
        "standard of care therapy"
      ]
    },
    {
      "Population": "Patients with advanced NSCLC with KRAS G12C mutation who have progressed after platinum-based chemotherapy and immunotherapy (where applicable) and have performance status 0-2",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sotorasib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with KRAS G12C and performance status 0-2 and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)"
      ],
      "Original_Comparator_Variants": [
        "sotorasib"
      ]
    },
    {
      "Population": "Patients with advanced NSCLC with KRAS G12C mutation who have progressed after platinum-based chemotherapy and immunotherapy (where applicable) and have performance status 0-2",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "adagrasib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with KRAS G12C and performance status 0-2 and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)"
      ],
      "Original_Comparator_Variants": [
        "adagrasib"
      ]
    },
    {
      "Population": "Patients with advanced NSCLC with KRAS G12C mutation who have progressed after platinum-based chemotherapy and immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed on or could not tolerate platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed on or could not tolerate platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel plus nintedanib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel plus nintedanib"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after platinum-containing chemotherapy and anti-PD-1/PD-L1 therapy (combined or sequential)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with locally advanced and unresectable or metastatic NSCLC with molecularly diagnosed KRAS G12C mutation. Patients had to have disease progression during or after at least 1 prior systemic therapy for advanced or unresectable stage of the disease. Prior therapy should include combined or sequential platinum-containing combination chemotherapy and an anti-PD-1/PD-L1."
      ],
      "Original_Comparator_Variants": [
        "docetaxel"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is appropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "afatinib, pemetrexed, erlotinib, docetaxel plus ramucirumab, docetaxel plus nintedanib, vinorelbine",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy"
      ],
      "Original_Comparator_Variants": [
        "Patient-individual therapy, taking into account previous therapy and histology with selection of afatinib, pemetrexed, erlotinib, docetaxel in combination with ramucirumab, docetaxel in combination with nintedanib and vinorelbine"
      ]
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "different chemotherapies without platinum (cisplatin/carboplatin) as well as treatment with an immune checkpoint inhibitor as monotherapy",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "different chemotherapies without platinum (cisplatin/ carboplatin) as well as treatment with an immune checkpoint inhibitor as monotherapy"
      ]
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel (only for patients with PD-L1 negative tumours)",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel (only for patients with PD-L1 negative tumours)"
      ]
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed (only for patients with PD-L1 negative tumours and except in case of predominantly squamous histology)",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "pemetrexed (only for patients with PD-L1 negative tumours and except in case of predominantly squamous histology)"
      ]
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "nivolumab"
      ]
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab (only for patients with PD-L1 expressing tumours (PD-L1 expression â‰¥ 1% of tumour cells))",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "pembrolizumab (only for patients with PD-L1 expressing tumours (PD-L1 expression â‰¥ 1% of tumour cells))"
      ]
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "atezolizumab"
      ]
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel plus nintedanib (only for patients with PD-L1 negative tumours and adenocarcinoma histology)",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumours and adenocarcinoma histology)"
      ]
    },
    {
      "Population": "Patients with nonâ€“small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "chemotherapy",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with nonâ€“small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation"
      ],
      "Original_Comparator_Variants": [
        "chemotherapy"
      ]
    },
    {
      "Population": "Metastatic NSCLC harboring a KRAS mutation who received prior chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "erlotinib plus tivantinib",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "erlotinib-tivantinib"
      ]
    },
    {
      "Population": "Metastatic NSCLC harboring a KRAS mutation who received prior chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "gemcitabine",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "gemcitabine"
      ]
    },
    {
      "Population": "Metastatic NSCLC harboring a KRAS mutation who received prior chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel"
      ]
    },
    {
      "Population": "Metastatic NSCLC harboring a KRAS mutation who received prior chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "pemetrexed"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "adagrasib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy"
      ],
      "Original_Comparator_Variants": [
        "adagrasib"
      ]
    },
    {
      "Population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation who have failed at least one systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sotorasib",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "Patients with Stage IV NSCLC with a KRAS-G12C mutation should be treated according to Failure of at least one systemic therapy Targeted therapy"
      ],
      "Original_Comparator_Variants": [
        "Sotorasib"
      ]
    },
    {
      "Population": "Patients with advanced NSCLC with KRAS G12C mutation who have been treated with immunotherapy monotherapy in the first line",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "platinum-based chemotherapy regimens (e.g., cisplatin-vinorelbine, cisplatin-gemcitabine, carboplatin-paclitaxel, cisplatin-docetaxel, cisplatin-pemetrexed [non-epidermoid only])",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients treated with immunotherapy monotherapy in the first line"
      ],
      "Original_Comparator_Variants": [
        "chemotherapy based on platinum salts, such as in the 1st line: cisplatin-vinorelbine, cisplatine-citagembine, carboplatin-paclitaxel, cisplain-docetaxel, Cisplatin-pemetrexed (non-epidermoid only)"
      ]
    },
    {
      "Population": "Patients with advanced NSCLC with KRAS G12C mutation who have been treated with chemotherapy plus immunotherapy in the first line",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed, docetaxel (non-epidermoid only)",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients treated with chemotherapeutic therapy + immunotherapies in the line 1"
      ],
      "Original_Comparator_Variants": [
        "chemotherapists in the single line: pemetrexed, docetaxel (non-epidermoside only)"
      ]
    },
    {
      "Population": "Patients with advanced NSCLC with KRAS G12C mutation who have received first-line platinum doublet chemotherapy without immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab, nivolumab, pembrolizumab (if PD-L1 â‰¥ 1%)",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients receiving first line bi-chemotherapy, without immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "immunotherapeutic treatment is the reference: atezolizumab, nivolumab or pembrolizimab (if PD-L1 â‰¥ 1%)"
      ]
    },
    {
      "Population": "Tumours expressing PD-L1 with a TPS â‰¥1%",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "tumours expressing PD-L1 with a TPS >=1%"
      ],
      "Original_Comparator_Variants": [
        "pembrolizumab"
      ]
    },
    {
      "Population": "Treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "",
      "Countries": [
        "EU",
        "PO",
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline",
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context"
      ],
      "Original_Comparator_Variants": [
        "",
        "",
        ""
      ]
    }
  ]
}